Clinical Trial

Twice-per-weekSelinexor, 2 Days Melphalan

Name: Twice-per-weekSelinexor, 2 Days Melphalan — clinical trial record (NCT06613035)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Twice-per-week Selinexor, 2 days Melphalan plus BU2FLU3 compared with BU3FLU5 for elder high-risk acute myeloid leukemia undergoing allogenic hematopoietic cell transplantation: a multi-center randomized phase 3 trial

Trial Details

NCT Number	NCT06613035
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Acute Myeloid Leukemia
Enrollment	126 participants
Start Date	2024-09-30
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2024-09-25